Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12

Journal of Virology

Volumn 75, Issue 14, 2001, Pages 6692-6699

  Zwick, M B ^a   Bonnycastle, L L C ^a   Menendez, A ^a   Irving, M B ^a   Barbas III, C F ^a   Parren, P W H I ^a   Burton, D R ^a   Scott, J K ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; BINDING SITE; DISULFIDE BOND; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN ANALYSIS; VIRUS ENVELOPE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; PEPTIDES; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; VIRAL ENVELOPE PROTEINS;

EID: 0034984611     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.14.6692-6699.2001     Document Type: Article

References (36)

1. Is clearance of HIV-1 viremia at seroconversion mediated by neutralising antibodies?
2. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries
3. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution
4. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage
5. Neutralization escape in human immunodeficiency virus type 1 infected long-term nonprogressors
6. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
7. Efficient neutralization of primary isolates of HIV 1 by a recombinant human monoclonal antibody
8. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
9. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
10. The role of structure in antibody cross-reactivity between peptides and folded proteins
11. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy
12. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
13. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus
14. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
15. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
16. NMR structure of the principal neutralizing determinant of HIV-1 displayed in filamentous bacteriophage coat protein
17. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
18. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination
19. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
20. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
21. Protection of macaques against vaginal transmission of a pathogenic HIV 1/SIV chimeric virus by passive infusion of neutralizing antibodies
22. ACH320
23. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors
24. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
25. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus
26. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
27. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant
28. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
29. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
30. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
31. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
32. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
33. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
34. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
35. Homodimeric peptides displayed by the major coat protein of filamentous phage